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Abstract
Background The acceptability of switching between ref-
erence drugs and their biosimilars is often disputed. It is
unclear whether this concern is specific to the use of
biosimilars or is relevant to the practice of switching
between any biological drugs.
Objective The objective of this study was to quantify the
occurrence of switching between different erythropoiesis-
stimulating agents.
Methods A retrospective drug utilization study was con-
ducted in the Umbria region (Italy). The study population
included all residents who received their first epoetin pre-
scription between 1 July 2011 and 31 December 2014. The
Umbria drug prescription database and the regional archive
of residents were used to gather information. Switching
was defined as any transition between different epoetins
(different substances and/or different products of the same
substance) in a series of two prescriptions. The probability
of switching was described in relationship to the duration
of treatment in a survival analysis.
Results Overall, 3258 subjects received prescriptions of
epoetins. Among the 2896 patients with at least two pre-
scriptions, 354 (12.2 %) experienced one or more switches.
The probability of switching depended on the duration of
treatment: approximately 15 % of users switched within
12 months of observation and 25 % switchedwithin 2 years.
Switching was not limited to reference and biosimilar epo-
etins and it affected patent and off-patent epoetins equally.
Conclusions Switching between different epoetins was
related to the duration of use and most episodes of
switching involved epoetins that have never been con-
trasted in a comparability exercise. The present level of
switching may provide reassurance to physicians when
taken together with other sources of comparative evidence.
Key Points
The probability of switching between different
epoetins was associated with the duration of
treatment: about 15 % of users switched within
12 months and almost 25 % within 2 years of
observation.
When switched from the reference epoetin, the
majority of subjects (61.8 %) received another
patented epoetin and 38.2 % received a biosimilar
epoetin. Initial users of other patented epoetins were
mainly shifted to a different product within the same
category (67.1 %).
The phenomenon of switching was not restricted to
the replacement of reference epoetins with biosimilar
epoetins, but also extended to products that have not
been directly compared in clinical studies.
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article (doi:10.1007/s40259-015-0155-0) contains supplementary
material, which is available to authorized users.
& Giuseppe Traversa
giuseppe.traversa@iss.it
1 Pharmacoepidemiology Unit, National Centre for
Epidemiology, National Institute of Health, Viale Regina
Elena 299, 00161 Rome, Italy
2 Unit for Pharmaceutical Governance, General Directorate for




Marketing of biosimilars represents an opportunity for
significant savings in pharmaceutical expenditure. How-
ever, despite the approval of biosimilars being preceded by
tests that document their equivalence to the reference
products, their use is the subject of ongoing debate in
clinical practice, mainly concerning the acceptability of
switching between a reference drug and its biosimilars (in
patients already treated with a reference product).
In order to be commercialized, a biosimilar must be pro-
ven equivalent to the reference product in terms of quality,
safety, and effectiveness. This comparability exercise, which
is the basis of the marketing authorization, should be con-
sidered sufficiently reassuring. For erythropoietin-stimulat-
ing agents (hereafter referred to as epoetins), clinical trials
include two study phases: the correction and themaintenance
phases. To be included in the maintenance phase, patients
should be optimally titrated with the reference epoetin
(stable hemoglobin in the target range with a stable epoetin
dose) for a suitable duration of time. Thereafter, study sub-
jects are randomized to either the biosimilar or the reference
epoetin [1]. Thus, pre-registration trials establish not only the
therapeutic equivalence of the two products, but also that
switching from reference to a biosimilar product is not
associated with an increased risk of adverse events [2, 3].
Nevertheless, some documents, as well as numerous
debates, on the use of biosimilars reiterate that biosimilars
may represent a more efficient (less costly) option for the
treatment of ‘naı¨ve’ subjects [4], whereas it is preferable that
therapeutic continuity be guaranteed for every treated patient
[5] because the safety of the substitution between originators
and their biosimilars is not considered to be supported by
robust studies [6]. This position does not take into account that
switching between different products of the same therapeutic
category, not only between reference and biosimilar drugs,
may be relatively common in clinical practice. If this were the
case, it would provide an indirect justification for the option of
switching between reference and biosimilar epoetins.
To date, few studies have investigated the frequency
with which biological products of the same therapeutic
category are substituted in clinical practice. The aim of the




The study was conducted in the Umbria region (about
900,000 inhabitants) of Italy in the period between 1 July
2011 and 31 December 2014. All residents (without age
restriction) who received a first prescription of an epoetin
during the study period and without prescriptions in the
previous 6 months (incident users) were included in the
analysis.
2.2 Data Source
In Italy, epoetins are covered free of charge by the National
Health Service on the basis of a prescription issued by the
general practitioner upon presentation of a treatment plan
filled in by a specialist. The medication can be dispensed
through local health units or community pharmacies. To
activate the reimbursement procedure, the dispensing
pharmacies are required to create a dispensing record in the
appropriate regional database. For each dispensing record,
the patient identifier, number of dispensed packages, drug
authorization code, and date of dispensation were retrieved.
Information on substances and on the expected duration of
the prescription on the basis of the defined daily doses
contained in each package were identified. Patients’
demographic information was acquired through the archive
of residents in the Umbria region. No information was
available on the indication (e.g., chronic kidney disease or
cancer) for the epoetin prescription or on drug use during
hospitalization.
2.3 Study Drugs
The following epoetins were prescribed in the Umbria
region during the study period: epoetin alfa (Eprex and
Binocrit), epoetin beta (Neorecormon), epoetin zeta
(Retacrit), darbepoetin alfa (Aranesp and Nespo), and
methoxypolyethyleneglycol–epoetin beta (Mircera). The
analysis was performed by grouping the different sub-
stances as ‘‘reference epoetin’’ (Eprex), ‘‘biosimilar epo-
etins’’ (Binocrit and Retacrit), and ‘‘other patented
epoetins’’ (Aranesp, Nespo, Mircera, and
NeoRecormon).
2.4 Definition of Switching
On the basis of the first prescription, subjects were classi-
fied as users of reference epoetin, of biosimilar epoetins,
and of other patented epoetins. Patients were followed from
the first prescription until the first of the following events:
switching, last prescription, or end of the study period.
Switching was defined as any transition between (substi-
tution of) different products in a series of two prescriptions;
switching might concern different substances (e.g., epoetin
alfa vs. epoetin beta) as well as different products of the
same substance (e.g., Binocrit vs. Retacrit; reference vs.
biosimilar epoetins). Switches could occur at any time
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during the study period, up to a maximum observation time
of 42 months.
2.5 Data Analysis
Descriptive analyses by age and sex of the study population
were conducted. The probability distribution of switching
was related to the months of treatment in a survival anal-
ysis (Kaplan–Meier). This analysis was performed includ-
ing users with at least two prescriptions and distinguishing
between users of reference epoetin, biosimilar epoetins,
and other patented epoetins. Two sensitivity analyses were
conducted: by year of the first prescription; and, in patients
who had more than one epoetin dispensed, after the first
switch during the study period (to describe the character-
istics of the second switch). The age and sex of the study
subjects were tested as possible determinants of switching
and the association was assessed using a Chi-squared (v2)
test. P values\0.05 were considered statistically signifi-
cant. The statistical analysis was performed using
STATA software (version 11.2; StataCorp LP, College
Station, TX, USA).
3 Results
During the study period 3258 subjects received at least one
epoetin prescription (3.6 per 1000 inhabitants). Users had a
median age of 79 years, with similar sex distribution. Each
user received an average of 14 prescriptions and only
11.1 % were sporadic users (one prescription in the study
period) (Table 1). Most epoetin users were prescribed
products categorized as other patented epoetins (n = 2545;
78.1 %) and a relatively small proportion of patients
received either reference (n = 446; 13.7 %) or biosimilar
epoetins (n = 267; 8.2 %). The three cohorts were quite
similar in terms of demographic characteristics, although
users of other patented epoetins had a median age
(80 years) slightly higher than that of other users (73 and
77 years, respectively, for users of reference and biosimilar
epoetins) (Table 1). The use of biosimilar epoetins was
very low in 2011 (0.7 %) and 2012 (1.8 %) and increased
to 9 and 18.3 % in 2013 and 2014, respectively (Fig. 1).
3.1 Analysis of Switching
Among the 2896 patients with at least two prescriptions of
epoetins, 354 (12.2 %) experienced at least one switch in
the study period. When switched from the reference epo-
etin (n = 68), the majority of subjects (n = 42; 61.8 %)
received one of the other patented epoetins and 38.2 %
(n = 26) received one biosimilar epoetin (Table 2). Users
of other patented epoetins (n = 246) were mainly shifted
to a different product within the same category (n = 165;
67.1 %).
The probability of switching was associated with the
duration of treatment: approximately 15 % of users swit-
ched within 12 months and almost 25 % switched within
2 years of observation (Fig. 2). A similar picture was
observed when the three cohorts (users of other epoetins,
reference epoetin, and biosimilar epoetins) were analyzed
separately. The probability of switching did not differ
between men and women or by different age classes
(Table 3). Moreover, no difference was observed when the
analysis was stratified by year of first prescription (see the
Electronic Supplementary Material).
Table 1 Characteristics of patients dispensed at least one epoetin prescription in the Umbria region population (2011–2014)
Users of reference




(n = 2545) [n (%)]
Users of biosimilar
epoetinsc (n = 267)
[n (%)]




Male 259 (58.1) 1339 (52.6) 137 (51.3) 0.08 1735 (53.3)
Female 187 (41.9) 1206 (47.4) 130 (48.7) 1523 (46.7)
Median age (years) 73 80 77 0.003 79
Number of prescriptions per user (mean) 15.0 13.8 14.3 0.9 14.0
Users with at least two prescriptions 387 (86.8) 2266 (89.0) 243 (91.0) 0.2 2896 (88.9)
Switchers 68 (17.6) 246 (10.9) 40 (16.5) \0.005 354 (12.2)
Female 28 (41.2) 108 (43.9) 15 (37.5) 0.7 151 (42.7)
Median age (years) 75 79 76 0.7 79
a Reference epoetin: epoetin alfa (Eprex)
b Other patented epoetins: darbepoetin alfa (Aranesp, Nespo), methoxypolyethyleneglycol–epoetin beta (Mircera), and epoetin beta
(NeoRecormon)
c Biosimilar epoetins: epoetin alfa (Binocrit) and epoetin zeta (Retacrit)
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The analysis of the second switch involved 38.9 %
(n = 130) of the 334 patients who received at least one
prescription after their first switch. The same prescriptive
pattern already observed after the first switch could be seen
at the second switch (Table 4).
4 Discussion
We were able to trace all prescriptions of epoetins in a
4-year period for the entire population of the Umbria
region. The analysis showed that the probability of
switching increased with the duration of therapy, reaching
25 % in subjects who were treated for up to 24 months.
Switching equally affected all users and was not restricted
to reference and biosimilar epoetins, suggesting that the
likelihood of switching is unrelated to the evidence pro-
vided by comparability exercises.
In a study conducted in Southern Italy, Loiacono et al.
[7] found a higher prevalence of users (5.5 per 1000
inhabitants) than observed in Umbria (3.6 per 1000
inhabitants). Moreover, they also estimated a larger pro-
portion of patients would switch between different products
(21.8 %) in the 1.5 years of follow-up [7] versus 12.2 %
over 2 years in the present study. The large variability in
the prescribing pattern of epoetins reported in the Italian
regions [8] might explain the differences observed in the
estimates of switching. A recent population-based study
analyzing the patterns of epoetin use in a large cohort of
Italian outpatients found a high degree of heterogeneity of
epoetin use across different Italian regions ranging from
1.5 per 1000 inhabitants in the Veneto region to more than
3.0 per 1000 inhabitants in the Sicily region in 2013 [9].
No other observational studies are currently available
regarding the frequency of switching between epoetins in
relation to the duration of therapy. What is well-docu-
mented, however, is that substituting different epoetins was
not associated with the occurrence of adverse events. Data
supporting the safety of switching mostly derive from
crossover studies in which the therapeutic regimen of all
patients admitted to a hospital or a hemodialysis unit was
modified. Ebbers et al. [2] identified 35 crossover studies
that evaluated the safety of switching between different
epoetins (regardless of whether reference, biosimilar, or
other patented epoetins) in a total of 11,249 patients.
Although these studies were generally too short to exclude
the occurrence of long-term adverse events, no safety
problems were reported in association with switching [2].
An analysis by Wie˛cek et al. [3] evaluated the impact of
switching from epoetin alfa to epoetin zeta, or vice versa,
in patients with chronic kidney disease. The study showed
that treatment with epoetin alfa or epoetin zeta could be
exchanged without any clinically relevant effects (in terms






























Fig. 1 Distribution of epoetin prescribing in the Umbria region
between 2011 and 2014. Reference epoetin: epoetin alfa (Eprex);
other patented epoetins: darbepoetin alfa (Aranesp, Nespo),
methoxypolyethyleneglycol–epoetin beta (Mircera), and epoetin
beta (NeoRecormon); biosimilar epoetins: epoetin alfa (Binocrit)
and epoetin zeta (Retacrit). DDD defined daily dose
Table 2 Patients dispensed at least two prescriptions for epoetin and who switched epoetin type between 2011 and 2014 in the Umbria region,
Italy
Epoetin at first prescription Epoetin at first switch [n (%)]
Reference epoetina Other patented epoetinsb Biosimilar epoetinsc Total
Reference epoetina 42 (61.8) 26 (38.2) 68
Other patented epoetinsb 52 (21.1) 165 (67.1) 29 (11.8) 246
Biosimilar epoetinsc 23 (57.5) 11 (27.5) 6 (15.0) 40
Total 75 (21.2) 218 (61.6) 61 (17.2) 354
a Reference epoetin: epoetin alfa (Eprex)
b Other patented epoetins: darbepoetin alfa (Aranesp, Nespo), methoxypolyethyleneglycol–epoetin beta (Mircera), and epoetin beta
(NeoRecormon)
c Biosimilar epoetins: epoetin alfa (Binocrit) and epoetin zeta (Retacrit)
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Among the obstacles to the use of biosimilars in clinical
practice, there are two main uncertainties often referred to
by physicians: (1) the safety of long-term use of these
products; and (2) the safety of switching between reference
and biosimilar products. The first concern will probably
lessen with time, with the increasing number of patients
being treated with biosimilars. In our opinion, the issue of
switching might be more difficult to overcome because the
evidence derived from the comparability exercise that
precedes biosimilar marketing should already be sufficient
to convince physicians.
The European Medicines Agency entrusted physicians
with the responsibility of substitutions between reference
and biosimilar products [10] and each European country
adopted specific policies [11]. If the diffusion of biosimi-
lars is to be encouraged, its use cannot be limited to naı¨ve
patients. It inevitably requires that both European and
national medicines agencies, as well as scientific societies,
are more proactive in presenting the transition from refer-
ence to biosimilar products as a safe option. The awareness
that switching is frequently conducted between products
that have not gone through a comparability exercise may
represent a further argument that can be used in discussions
with physicians.
The main limitations of our study concern the lack of
information on the indication for the prescriptions (e.g.,
whether epoetins were prescribed in patients with renal or
oncological conditions) and on the reasons for switching.
As for other pharmacoepidemiological studies using pre-
scription databases, it was not possible to ascertain whether
the dispensed drug was actually taken by the patient;
however, as these drugs are indicated for chronic diseases,
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Fig. 2 Kaplan–Meier estimate
for time to first switch among
patients dispensed at least two
epoetin prescriptions between
2011 and 2014 in the Umbria
region of Italy. The inset graph
shows the time to switch in the
cohorts of users of other
patented epoetins (O, red line),
reference epoetin (R, green
line), and biosimilar products
(B, blue line). The
corresponding 95 % confidence
interval is represented by
shaded regions
Table 3 Patients dispensed at
least two prescriptions for
epoetins (n = 2896) and who
switched epoetin type in the
Umbria region, Italy
(2011–2014): stratified by age
and sex
Switchers (n = 354)
[n (%)]




Female 151 (42.6) 1206 (47.4) 0.09
Male 203 (57.4) 1336 (52.6)
Age (years)
B50 24 (6.8) 149 (5.8) 0.3
51–60 23 (6.5) 192 (7.6)
61–70 49 (13.8) 339 (13.3)
71–80 112 (31.6) 688 (27.1)
?81 146 (41.2) 1174 (46.2)
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5 Conclusions
Our study shows that switching is related to the duration of
drug therapy and equally affects all epoetins. The practice
of switching mainly concerns drugs that have not under-
gone the direct comparability testing that is carried out
before marketing a biosimilar product. These data, when
taken together with other sources of comparative evidence,
may provide reassurance to physicians regarding the sub-
stitution of reference with biosimilar epoetins.
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Table 4 Type of epoetin received at the second switch among users of reference epoetin, biosimilar epoetins, and other patented epoetins in the
Umbria region, Italy (2011–2014)
Epoetin at first switch Epoetin at second switch [n (%)]
Reference epoetina Other patented epoetinsb Biosimilar epoetinsc Total
Reference epoetina 18 (56.3) 14 (43.7) 32 (24.6)
Other patented epoetinsb 17 (22.7) 52 (69.3) 6 (8.0) 75 (57.7)
Biosimilar epoetinsc 14 (60.9) 9 (39.1) 0 (0.0) 23 (17.7)
Total 31 (23.8) 79 (60.8) 20 (15.4) 130
a Reference epoetin: epoetin alfa (Eprex)
b Other patented epoetins: darbepoetin alfa (Aranesp, Nespo), methoxypolyethyleneglycol–epoetin beta (Mircera), and epoetin beta
(NeoRecormon)
c Biosimilar epoetins: epoetin alfa (Binocrit) and epoetin zeta (Retacrit)
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